- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
VIDEO: Susan Urba, MD, Discusses Chemotherapy-Induced Nausea and Vomiting
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that treatment-related factors used to stratify patients to prevent chemotherapy-induced nausea and vomiting are the actual chemotherapy drugs.
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that treatment-related factors used to stratify patients to prevent chemotherapy-induced nausea and vomiting are the actual chemotherapy drugs. Dr Urba says that there are specific lists of medications that breakdown the medications into categories, such as highly emetogenic and moderately emetogenic. Dr Urba uses the medication cisplatin as an example of one of the widely used, highly emetogenic treatments used.
This video was taken on November 9 at the NAMCP Fall Managed Care Forum in Las Vegas, NV.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
